ERBB2 and breast cancer: However, a significant association of the clinicopathological characteristics such as late stage at diagnosis, HER2/neu receptor negative status and presence of metastasis with 5- years survival rate was observed (p<0.05), suggesting the importance of these clinicopathological features in the progression of breast cancer.